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Supplementary Material 
1. BriTROC investigators and Trial Management Group 
Sites, investigators and numbers recruited 
Beatson West of Scotland Cancer Centre, Glasgow – Rosalind M Glasspool, Iain McNeish, 52 
Addenbrooke’s Hospital, Cambridge – James D Brenton, 29 
St Bartholomew’s Hospital, London – Michelle Lockley, Elly Brockbank, 28 
Hammersmith Hospital, London – Hani Gabra, Christina Fotopoulou, 27 
Mount Vernon Cancer Centre, Northwood – Marcia Hall, 20 
Western General Hospital, Edinburgh – Charlie Gourley, 16 
St James University Hospital, Leeds – Geoff Hall, 11 
The Christie Hospital, Manchester – Andrew Clamp, 11 
Guy’s and St Thomas’ Hospitals, London – Ana Montes, 6 
St Mary’s Hospital, Manchester – Richard Edmondson, 6 
Bristol Haematology and Oncology Centre, Bristol – Axel Walther, 5 
City Hospital, Birmingham – Sudha Sundar, 4 
Queen Elizabeth Hospital, Gateshead – Raj Naik, 3 
Belfast City Hospital – Richard Kennedy, 2 
  
Lead pathologists 
Queen Elizabeth University Hospital, Glasgow – David Millan 
Addenbrooke’s Hospital, Cambridge – Mercedes Jimenez-Linan 
  
Trial Management Group 
Iain McNeish (co-Chief Investigator), James Brenton (co-Chief Investigator) Liz-Anne Lewsley (Project 
Manager), James Paul (Study Statistician), Hani Gabra (Investigator), Darren Ennis (Translational 
Research Scientist), Cheryl Wilson (study co-ordinator), Paul Dearie (Sponsor Representative). 
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2. Full inclusion and exclusion criteria 
Inclusion 
1.          Patients with recurrent histologically-proven ovarian cancer, primary peritoneal carcinoma or 
fallopian tube cancer of high grade serous and high grade endometrioid subtypes.  Patients who have 
a diagnosis of ovarian cancer with a known germline mutation in BRCA1 or BRCA2 will also be eligible 
for inclusion regardless of histological subtype. Patients who are having a diagnostic image-guided 
biopsy maybe consented and study biopsy taken while awaiting pathological review.  Eligible patients 
who have had samples collected under generic research consent may be registered retrospectively 
only after full discussion between the site, Chief Investigator and the co-ordinating trials unit (and 
BriTROC-1 specific consent obtained). 
2.          Patients must have received at least one line of platinum-containing chemotherapy 
3.          Availability of formalin-fixed, paraffin-embedded tissue taken at the time of original diagnosis of 
high grade serous ovarian cancer.  This may be primary surgical debulking specimen OR core biopsy. 
For those with only a core biopsy from time of diagnosis, availability of specimen taken at interval 
debulking surgery is desirable, but not essential. 
4.          Patients must have disease deemed suitable for imaging-guided biopsy (ultrasound or CT) by an 
experienced radiologist or suitable for intra-operative biopsy during secondary debulking surgery as 
determined by an experienced gynaecological oncology surgeon. Other biopsies, such as skin 
deposits, are also acceptable.  However, this must be confirmed with the Cancer Research UK Clinical 
Trials Unit prior to patient registration. 
5.          Age ≥ 18 years. 
6.          Written informed consent. 
7.          Able to apply with study procedures. 
8.          Life expectancy > 3 months 
9.          No contraindication to biopsy as appropriate. 
  
Exclusion 
1.          Ovarian, primary peritoneal or fallopian tube cancer of low grade serous, grades 1 or 2 
endometrioid, clear cell or carcinosarcoma/malignant mixed mesodermal (MMMT) subtypes unless 
associated with known germline mutation in BRCA1 or BRCA2. 
2.          Borderline/low malignant potential tumours 
3.          Any non-epithelial ovarian malignancy 
4.          Patients with asymptomatic rising CA125 with no radiological evidence of recurrent ovarian 
cancer. 
5.          Original diagnosis of high grade serous cancer made on cytology only 
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3. Ineligibility and declining to participate 
  
BriTROC-1 Screening Logs   
1.    Patient ineligible 182 
2.    Patient declined as unhappy with proposed trial 38 
3.    Patient declined for other reason 79 
TOTAL 299 
Reasons for ineligibility   
Is the patient over 18 years of age? 0 
Has the patient given written informed consent? 0 
Does the patient have recurrent histologically proven ovarian cancer, primary peritoneal 
carcinoma or fallopian tube cancer of high grade serous and high grade endometrioid 
subtypes. Patients who have a diagnosis of ovarian cancer with a known germline mutation 
in BRCA1 or BRCA2 will also be eligible for inclusion regardless of histological subtype. 
Patients who are having a diagnostic image-guided biopsy may be consented and study 
biopsy taken while awaiting pathological review.  Eligible patients who have had samples 
collected under generic research consent may be registered retrospectively only after full 
discussion with the site, Chief Investigator and CR-UK CTU (and BriTROC-1 specific consent 
obtained) 
8 
Has the patient received at least one line of platinum-containing chemotherapy 0 
Please confirm that there is formalin-fixed, paraffin embedded tissue taken at the time of 
original diagnosis of high grade serous ovarian cancer available? 
11 
Does the patient have disease deemed suitable for imaging-guided/intra-operative or other 
suitable biopsy 
90 
Is the patient able to comply with study procedures? 11 
Does the patient have a life expectancy of > 3 months? 0 
Is it confirmed that there is no contraindication to biopsy? 23 
Does the patient have an ovarian, primary peritoneal or fallopian tube cancer of low grade 
serous, grades 1 or 2 endometrioid, clear cell or carcinosarcoma/MMMT subtypes unless 
associated with known germline mutation BRCA1 or BRCA2 
10 
Does the patient have a borderline/low malignant potential tumour? 0 
Does the patient have a non-epithelial ovarian malignancy 0 
Does the patient have an asymptomatic rising CA125 with no radiological evidence of 
recurrent ovarian cancer? 
4 
Was the original diagnosis of high grade serous cancer made on cytology only? 9 
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Not stated 16 
TOTAL 182 
Declined – other reason   
Patient did not want biopsy 5 
Commencing chemotherapy treatment asap 12 
Felt she had 'too much going on' 8 
Patient opted for treatment with another study 1 
Patient prefers supportive care locally therefore not approached 1 
Did not wish to undergo biopsy due to previous painful biopsy experience at another hospital 2 
Patient did not want extra tests/visits 4 
Patient too unwell for chemo or biopsy 2 
Patients family not happy for her to participate 2 
Patient accepted but started treatment sooner than planned 1 
Area to be biopsied too painful 1 
Patient cannot commit 1 
Patient too distressed by progression 2 
Not well enough 2 
Patient's husband is ill 2 
Psychologically not able to cope with anything else (depression) 1 
Not happy to take part in any research 1 
Patient not feeling up to it 2 
Unable to attend for biopsy on only day available 1 
Not interested in participation 2 
Biopsy at diagnosis and found it very traumatic 1 
Eligible but having urgent radiotherapy 1 
Patient discussed at MDT - Research Nurses not informed - pt proceeded to 
surgery 
2 
Consultant decided trial not appropriate 1 
Patient transferred to another hospital 3 
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Patient entered another trial 2 
Unspecified 11 
No information received 5 
TOTAL 79 
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4. Prior chemotherapy lines and time from diagnosis to 
recruitment 
Time to recruitment from diagnosis for platinum sensitive relapse (left) and platinum resistant relapse 
(right) patients, grouped by lines of prior chemotherapy.  Each point () represents one patient. 
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5. Overall survival 
Overall survival of patients recruited in Glasgow (n=52) and Edinburgh (n=16) from time of consent.  
Pt_sensitive - platinum-sensitive (relapse ≥6 months following previous platinum-based 
chemotherapy).  Pt_resistant (relapse <6 months following previous platinum-based chemotherapy. 
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6.  Adverse events 
  
Trial No Complications 
Following 
Biopsy type AE Grade Relationship To 
Biopsy 
1 Baseline biopsy Image-guided 
biopsy 
Pain 2 Probable 
14 Baseline biopsy Image-guided 
biopsy 
Pain 1 Probable 
14 2nd biopsy Image-guided 
biopsy 
Postoperative Haemorrhage (post 
biopsy) 
1 Probable 
14 2nd biopsy Image-guided 
biopsy 
Pain 1 Probable 
16 Baseline biopsy Image-guided 
biopsy 
Pain 2 Possible 
25 Baseline biopsy Image-guided 
biopsy 
Postoperative Haemorrhage (post 
biopsy) 
2 Definite 
25 Baseline biopsy Image-guided 
biopsy 
Pain 2 Definite 
54 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
59 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
79 Baseline biopsy Image-guided 
biopsy 
General disorders and 
administration site conditions – 
Other (haematoma) 
1 Definite 
106 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
116 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
123 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
130 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
136 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
148 Baseline biopsy Image-guided 
biopsy 
Pain 1 Probable 
179 Baseline biopsy Image-guided 
biopsy 
Postoperative Haemorrhage (post 
biopsy) 
1 Definite 
179 Baseline biopsy Image-guided 
biopsy 
Vaginal discharge 2 Definite 
183 Baseline biopsy Image-guided Pain 1 Definite 
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biopsy 
192 Baseline biopsy Image-guided 
biopsy 
Pain 1 Possible 
201 Baseline biopsy Image-guided 
biopsy 
Postoperative Haemorrhage (post 
biopsy) 
1 Definite 
211 Baseline biopsy Image-guided 
biopsy 
Pain 1 Definite 
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7. Patient consent form  
 
 
Page 7 of 8 
BriTROC 1  
Patient Information Sheet & Consent Form 
Version 9, 26
th
 April 2016 
  
CONSENT FORM FOR PATIENTS/VOLUNTEERS IN A CLINICAL RESEARCH PROJECT 
(Form to be on hospital headed paper) 
 
Title of Project: BriTROC-1: sample collection study to investigate the role of Homologous 
Recombination Deficiency in platinum sensitivity in recurrent high grade serous ovarian cancer 
 
Principal Investigator:  
Patient Study Number:  
 
  Please 
initial box 
 
1.  I confirm that I have read and understand the information sheet dated 26
th 
April 2016 (Version 9) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
  
2.  I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected 
  
3.  I agree that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from the Cancer 
Research UK Clinical Trials Unit (Glasgow), the trial sponsor, the regulatory 
authorities and the NHS organisation where it is relevant to my taking part in 
research. I give permission for these individuals to have access to my records. 
  
4.  I agree to give tissue samples from my diagnosis for use in research related to 
this study as described in the patient information sheet.  
  
5.  I agree to give a 40 ml blood samples for research purposes as described in 
the patient information sheet. 
  
6.  I agree to give an ascitic fluid sample for research purposes if ascites is 
present and drainage is clinically indicated, as described in the patient 
information sheet.  
  
7.  I agree to the information detailed in this patient information sheet to be 
collected as part of this study. 
  
8.  I understand that the aforementioned samples will be held at the Institute for 
Cancer Sciences, University of Glasgow.   
  
9.  I understand that my samples may be retained by the Institute for Cancer 
Sciences, University of Glasgow, for use in future biological studies to help 
understand ovarian cancer. I understand that some of these projects may be 
carried out by researchers other than the BriTROC co-investigators. I 
understand that some of these projects may involve international 
collaborations.  All future research will be approved by a research ethics 
committee. 
  
10.  I agree to my GP being informed of my participation in this trial.   
11.  I agree that my routine data that are collected nationally, as described in the 
patient information sheet, can be accessed. 
  
12.  I agree to take part in this study   
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BriTROC 1  
Patient Information Sheet & Consent Form 
Version 9, 26
th
 April 2016 
  
 OPTIONAL Please initial 
box 
13.  I agree to two extra blood samples, taken just before first and second 
cycle of chemotherapy/anti-cancer treatment 
Yes 
 
No 
 
14.  If my cancer returns during the duration of this study, I agree to undergo a 
repeat biopsy and to give 40 ml blood samples for research purposes as 
described in the patient information sheet 
Yes 
 
No 
 
15.  I wish to be informed of any inherited mutations in DNA repair genes 
found during this research project and consent to a blood sample being 
sent for storage at the regional NHS Genetics Laboratory for confirmatory 
testing if appropriate.  If you or your family wish to be referred to the 
Clinical Genetics Service this can be arranged through your doctor. 
Yes 
 
No 
 
16.  In the event that I am no longer alive, I wish my next-of-kin to be informed 
of any inherited mutations in DNA repair genes found during this research 
project 
Yes 
 
No 
 
17.  I give permission for my initials, date of birth and NHS (or Community 
Health Index (CHI)) number to be collected by the Cancer Research UK 
Clinical Trials Unit (Glasgow), where they will be stored in a secure 
location.  I understand giving consent to the use of this data as described 
is optional and not mandatory for participating in this study. 
Yes 
 
No 
 
 
 
 
Name of Patient Date Signature 
 
 
__________________________ 
 
 
__________ 
 
 
___________________________ 
   
Name of person taking consent 
(designated responsible person) 
Date Signature 
 
 
__________________________ 
 
 
__________ 
 
 
____________________________ 
 
 
When completed, 1 original for patient, 1 original for researcher, 1 copy to be kept with hospital 
notes 
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8. R Markdown 
Teodora Goranova, Iain A. McNeish, James D. Brenton 
2017-02-27 
This is an R Markdown document. Markdown is a simple formatting syntax for authoring HTML, PDF, 
and MS Word documents. For more details on using R Markdown see http://rmarkdown.rstudio.com. 
Please use the Google R style guide, see https://google.github.io/styleguide/Rguide.xml. 
We first load required libraries and define Useful functions. 
Load data files 
We first load the raw data from 6 tables and derive factors. 
## Parsed with column specification: 
## cols( 
##   trialno = col_double(), 
##   platinum.status = col_character(), 
##   site = col_character(), 
##   reg.date = col_datetime(format = ""), 
##   diag.age = col_double(), 
##   study.age = col_double(), 
##   histo = col_character(), 
##   diagdate = col_datetime(format = ""), 
##   time.since.diag = col_double(), 
##   prior.lines.chemo = col_integer(), 
##   registration = col_character(), 
##   brca.status = col_character(), 
##   censor.date = col_datetime(format = ""), 
##   os.status = col_integer(), 
##   os.diag.months = col_double(), 
##   os.entry.months = col_double() 
## ) 
## Parsed with column specification: 
## cols( 
##   trialno = col_double(), 
##   start.date = col_datetime(format = ""), 
##   end.date = col_datetime(format = ""), 
##   numberof.cycles = col_double(), 
##   line.no = col_double(), 
##   drug = col_character(), 
##   dose = col_double(), 
##   units = col_character(), 
##   comment = col_character() 
## ) 
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## Parsed with column specification: 
## cols( 
##   trialno = col_double(), 
##   biopsy.sequence = col_character(), 
##   ae = col_character(), 
##   grade = col_double(), 
##   relationship.to.biopsy = col_character(), 
##   ae.details = col_character() 
## ) 
## Parsed with column specification: 
## cols( 
##   trialno = col_double(), 
##   biopsy.type = col_character(), 
##   needle.size = col_character(), 
##   biopsy.site = col_character(), 
##   biopsy.sequence = col_character(), 
##   needle.size.bin = col_character(), 
##   biopsy.site.recode = col_character() 
## ) 
## Parsed with column specification: 
## cols( 
##   trialno = col_double(), 
##   histo.no = col_character(), 
##   jblab.id = col_character(), 
##   biorepository.no = col_double(), 
##   biorepository.no.h.e = col_character(), 
##   nbf.umfix = col_character(), 
##   tumour.cellularity.comments = col_character(), 
##   tumour.cellularity = col_double(), 
##   tumour.cellularity.in.dissected.area = col_double(), 
##   dissection.method = col_character(), 
##   sections.for.dna.extraction = col_double(), 
##   dna.extraction.date = col_date(format = ""), 
##   kit.used.for.extraction = col_character(), 
##   elution.buffer = col_character(), 
##   dna.qubit.ng.ul = col_double(), 
##   volume.ul = col_double(), 
##   total.dna.ug = col_double(), 
##   comments.1 = col_character(), 
##   biopsy.sequence = col_character() 
## ) 
## Parsed with column specification: 
## cols( 
##   .default = col_character(), 
##   trialno = col_integer(), 
##   chromosome = col_integer(), 
##   position = col_integer(), 
##   af1 = col_double(), 
##   af2 = col_double(), 
##   depth1 = col_integer(), 
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##   depth2 = col_integer(), 
##   quality.1 = col_integer(), 
##   quality.2 = col_integer(), 
##   offset.from.primer.end = col_integer(), 
##   indel.length = col_integer(), 
##   af1.short = col_double(), 
##   af2.short = col_double(), 
##   depth1.short = col_integer(), 
##   depth2.short = col_integer(), 
##   mean.af = col_double(), 
##   mean.depth = col_double() 
## ) 
## See spec(...) for full column specifications. 
Patients 
Table 1: Demographic and disease characteristics 
Total number of patients 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   220 
Are there any duplicate trial no? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   220 
## # A tibble: 2 × 3 
##    registration     n rel.freq 
##           <chr> <int>    <dbl> 
## 1   Prospective   198      0.9 
## 2 Retrospective    22      0.1 
How many NA are there in the clin.data table? 
## # A tibble: 1 × 16 
##   trialno platinum.status  site reg.date diag.age study.age histo diagdate 
##     <int>           <int> <int>    <int>    <int>     <int> <int>    <int> 
## 1       0               0     0        0        0         2     0        2 
## # ... with 8 more variables: time.since.diag <int>, 
## #   prior.lines.chemo <int>, registration <int>, brca.status <int>, 
## #   censor.date <int>, os.status <int>, os.diag.months <int>, 
## #   os.entry.months <int> 
How many platinum sensitive vs. resistant? 
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## # A tibble: 2 × 3 
##                         platinum.status     n  rel.freq 
##                                   <chr> <int>     <dbl> 
## 1 Platinum resistant/refractory relapse    49 0.2227273 
## 2            Platinum sensitive relapse   171 0.7772727 
Key variables by platinum sensitivity. 
## # A tibble: 2 × 10 
##                         platinum.status study.age_median_ study.age_min_ 
##                                   <chr>             <dbl>          <dbl> 
## 1 Platinum resistant/refractory relapse          65.84658       25.04110 
## 2            Platinum sensitive relapse          69.44658       37.18904 
## # ... with 7 more variables: study.age_max_ <dbl>, 
## #   time.since.diag_median_ <dbl>, time.since.diag_min_ <dbl>, 
## #   time.since.diag_max_ <dbl>, prior.lines.chemo_median_ <int>, 
## #   prior.lines.chemo_min_ <int>, prior.lines.chemo_max_ <int> 
Key variables in whole group. 
## # A tibble: 1 × 9 
##   study.age_median_ study.age_min_ study.age_max_ time.since.diag_median_ 
##               <dbl>          <dbl>          <dbl>                   <dbl> 
## 1          68.21644        25.0411       92.52329                31.00275 
## # ... with 5 more variables: time.since.diag_min_ <dbl>, 
## #   time.since.diag_max_ <dbl>, prior.lines.chemo_median_ <dbl>, 
## #   prior.lines.chemo_min_ <int>, prior.lines.chemo_max_ <int> 
What was BRCA status by platinum status? 
## Source: local data frame [10 x 4] 
## Groups: platinum.status [2] 
##  
##                          platinum.status brca.status     n  rel.freq 
##                                    <chr>       <chr> <int>     <dbl> 
## 1             Platinum sensitive relapse       BRCA1    11  6.432749 
## 2             Platinum sensitive relapse       BRCA2     7  4.093567 
## 3             Platinum sensitive relapse     Missing    63 36.842105 
## 4             Platinum sensitive relapse  Not tested    71 41.520468 
## 5             Platinum sensitive relapse   Wild-type    19 11.111111 
## 6  Platinum resistant/refractory relapse       BRCA1     3  6.122449 
## 7  Platinum resistant/refractory relapse       BRCA2     5 10.204082 
## 8  Platinum resistant/refractory relapse     Missing    14 28.571429 
## 9  Platinum resistant/refractory relapse  Not tested    13 26.530612 
## 10 Platinum resistant/refractory relapse   Wild-type    14 28.571429 
What was BRCA status across whole group? 
## # A tibble: 5 × 3 
##   brca.status     n  rel.freq 
##         <chr> <int>     <dbl> 
## 1       BRCA1    14  6.363636 
## 2       BRCA2    12  5.454545 
## 3     Missing    77 35.000000 
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## 4  Not tested    84 38.181818 
## 5   Wild-type    33 15.000000 
What were histologies by platinum status? 
## Source: local data frame [5 x 4] 
## Groups: platinum.status [2] 
##  
##                         platinum.status                  histo     n 
##                                   <chr>                  <chr> <int> 
## 1            Platinum sensitive relapse      High grade serous   160 
## 2            Platinum sensitive relapse Endometrioid (grade 3)     5 
## 3            Platinum sensitive relapse                Missing     5 
## 4            Platinum sensitive relapse         Carcinosarcoma     1 
## 5 Platinum resistant/refractory relapse      High grade serous    49 
## # ... with 1 more variables: rel.freq <dbl> 
What were histologies across whole group? 
## # A tibble: 4 × 3 
##                    histo     n   rel.freq 
##                    <chr> <int>      <dbl> 
## 1      High grade serous   209 95.0000000 
## 2 Endometrioid (grade 3)     5  2.2727273 
## 3                Missing     5  2.2727273 
## 4         Carcinosarcoma     1  0.4545455 
What were prior treatment regimes by platinum status? 
## Source: local data frame [13 x 4] 
## Groups: platinum.status [2] 
##  
##                          platinum.status prior.lines.chemo     n 
##                                    <chr>             <int> <int> 
## 1             Platinum sensitive relapse                 1   120 
## 2             Platinum sensitive relapse                 2    39 
## 3             Platinum sensitive relapse                 3     6 
## 4             Platinum sensitive relapse                 4     1 
## 5             Platinum sensitive relapse                 5     3 
## 6             Platinum sensitive relapse                NA     2 
## 7  Platinum resistant/refractory relapse                 1    17 
## 8  Platinum resistant/refractory relapse                 2    23 
## 9  Platinum resistant/refractory relapse                 3     1 
## 10 Platinum resistant/refractory relapse                 4     2 
## 11 Platinum resistant/refractory relapse                 5     4 
## 12 Platinum resistant/refractory relapse                 6     1 
## 13 Platinum resistant/refractory relapse                12     1 
## # ... with 1 more variables: rel.freq <dbl> 
What were prior treatment regimes across whole group? 
## # A tibble: 8 × 3 
##   prior.lines.chemo     n   rel.freq 
##               <int> <int>      <dbl> 
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## 1                 1   137 62.2727273 
## 2                 2    62 28.1818182 
## 3                 3     7  3.1818182 
## 4                 4     3  1.3636364 
## 5                 5     7  3.1818182 
## 6                 6     1  0.4545455 
## 7                12     1  0.4545455 
## 8                NA     2  0.9090909 
Biopsy features 
How many biopsies were performed? 
## Source: local data frame [7 x 3] 
## Groups: biopsy.type [?] 
##  
##    biopsy.type biopsy.sequence     n 
##          <chr>           <chr> <int> 
## 1 image-guided        baseline   118 
## 2 image-guided          second     7 
## 3      missing        baseline     1 
## 4        other        baseline     1 
## 5        other          second     1 
## 6     surgical        baseline    96 
## 7     surgical          second     3 
Did any patient have more than one sample obtained at baseline and second image-guided biopsy? 
## Source: local data frame [125 x 3] 
## Groups: trialno [119] 
##  
##    trialno biopsy.sequence     n 
##      <dbl>           <chr> <int> 
## 1        1        baseline     1 
## 2        2        baseline     1 
## 3        4        baseline     1 
## 4        5        baseline     1 
## 5        6        baseline     1 
## 6        7        baseline     1 
## 7        8        baseline     1 
## 8        9        baseline     1 
## 9       10        baseline     1 
## 10      12        baseline     1 
## # ... with 115 more rows 
What needle size was used for image-guided biopsies (baseline and second)? 
## # A tibble: 3 × 3 
##   needle.size     n     freq 
##         <chr> <int>    <dbl> 
## 1         18G    54 45.00000 
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## 2         16G    49 40.83333 
## 3         14G    17 14.16667 
Table 2: Biopsy locations 
What were the biopsy sites? 
## Source: local data frame [49 x 5] 
## Groups: biopsy.type, biopsy.sequence [7] 
##  
##     biopsy.type biopsy.sequence           biopsy.site     n      freq 
##           <chr>           <chr>                 <chr> <int>     <dbl> 
## 1  image-guided        baseline       peritoneum.abdo    27 22.881356 
## 2  image-guided        baseline              ln.other    26 22.033898 
## 3  image-guided        baseline                 liver    13 11.016949 
## 4  image-guided        baseline               omentum    12 10.169492 
## 5  image-guided        baseline subcut.abdochest.wall     9  7.627119 
## 6  image-guided        baseline     peritoneum.pelvic     7  5.932203 
## 7  image-guided        baseline             ln.retrop     6  5.084746 
## 8  image-guided        baseline             ln.pelvis     5  4.237288 
## 9  image-guided        baseline             vag.vault     4  3.389831 
## 10 image-guided        baseline        uterus.ov.tube     2  1.694915 
## # ... with 39 more rows 
What was the frequency by binned biopsy sites? 
## # A tibble: 10 × 3 
##       biopsy.site.recode     n      freq 
##                    <chr> <int>     <dbl> 
## 1             lymph.node    64 28.193833 
## 2             peritoneum    53 23.348018 
## 3                omentum    26 11.453744 
## 4                  other    19  8.370044 
## 5                  liver    17  7.488987 
## 6            gynae.organ    14  6.167401 
## 7  subcut.abdochest.wall    14  6.167401 
## 8    bowel.serosa.mesent    12  5.286344 
## 9              diaphragm     4  1.762115 
## 10          peri.splenic     4  1.762115 
Which biopsy sites are in the NA bin? 
## # A tibble: 0 × 2 
## # ... with 2 variables: biopsy.site <chr>, n <int> 
Which sites are included in gynae.organ bin? 
## # A tibble: 2 × 2 
##      biopsy.site     n 
##            <chr> <int> 
## 1 uterus.ov.tube     6 
## 2      vag.vault     8 
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Table 3: Adverse events 
We use a left join to join the adverse event table to the biopsies table, so all adverse events have 
biopsy details. 
## Joining, by = c("trialno", "biopsy.sequence") 
How many biopsies have adverse events? 
## Source: local data frame [5 x 3] 
## Groups: biopsy.type [?] 
##  
##    biopsy.type biopsy.sequence     n 
##          <chr>           <chr> <int> 
## 1 image-guided        baseline    20 
## 2 image-guided          second     2 
## 3        other        baseline     1 
## 4     surgical        baseline    14 
## 5         <NA>        baseline     1 
How many patients had adverse events after both baseline and second image-guided biopsy? 
## Source: local data frame [5 x 3] 
## Groups: biopsy.type [?] 
##  
##    biopsy.type biopsy.sequence no.patients 
##          <chr>           <chr>       <int> 
## 1 image-guided        baseline          18 
## 2 image-guided          second           1 
## 3        other        baseline           1 
## 4     surgical        baseline           9 
## 5         <NA>        baseline           1 
What adverse events occured after image-guided biopsy? 
## Source: local data frame [6 x 3] 
## Groups: ae [?] 
##  
##                                                                      ae 
##                                                                   <chr> 
## 1 General disorders and administration site conditions - Other, specify 
## 2                                                                  Pain 
## 3                                                                  Pain 
## 4                               Postoperative Haemorrhage (post biopsy) 
## 5                               Postoperative Haemorrhage (post biopsy) 
## 6                                                     Vaginal discharge 
## # ... with 2 more variables: grade <dbl>, n <int> 
What adverse events occurred by needle size? 
## Source: local data frame [10 x 4] 
## Groups: ae, needle.size [?] 
##  
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##                                                                       ae 
##                                                                    <chr> 
## 1  General disorders and administration site conditions - Other, specify 
## 2                                                                   Pain 
## 3                                                                   Pain 
## 4                                                                   Pain 
## 5                                                                   Pain 
## 6                                                                   Pain 
## 7                                Postoperative Haemorrhage (post biopsy) 
## 8                                Postoperative Haemorrhage (post biopsy) 
## 9                                Postoperative Haemorrhage (post biopsy) 
## 10                                                     Vaginal discharge 
## # ... with 3 more variables: needle.size <chr>, grade <dbl>, n <int> 
Were adverse events different between needle size? 
## Joining, by = c("trialno", "biopsy.sequence") 
##  
##  Pearson's Chi-squared test with Yates' continuity correction 
##  
## data:  foo$needle.size.bin and foo$ae.bin 
## X-squared = 0.22802, df = 1, p-value = 0.633 
Quality of biopsies 
DNA extraction 
We left join the tissue.dna data to the biopsies data. 
## Joining, by = c("trialno", "biopsy.sequence") 
How many unique patients? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   142 
How many unique samples had DNA extraction attempted? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   184 
What was the cellularity of dissected tumour area (irrespective of yield)? 
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How many dissected samples had cellularity > 0? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   163 
What was dissection method for all samples? 
## # A tibble: 3 × 2 
##   dissection.method     n 
##               <chr> <int> 
## 1             Macro    41 
## 2             Micro   122 
## 3              <NA>    21 
NA here stand for samples with no tumour cells. 
What was the type of samples that had cellularity > 0? 
## # A tibble: 2 × 3 
##    biopsy.type     n     freq 
##          <chr> <int>    <dbl> 
## 1 image-guided    88 53.98773 
## 2     surgical    75 46.01227 
What was the yield and cellularity in samples with cellularity > 0? 
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## # A tibble: 1 × 10 
##   total.dna.ug_min_ cellularity_min_ total.dna.ug_Q1_ cellularity_Q1_ 
##               <dbl>            <dbl>            <dbl>           <dbl> 
## 1                 0                5            0.844              45 
## # ... with 6 more variables: total.dna.ug_median_ <dbl>, 
## #   cellularity_median_ <dbl>, total.dna.ug_Q3_ <dbl>, 
## #   cellularity_Q3_ <dbl>, total.dna.ug_max_ <dbl>, cellularity_max_ <dbl> 
What was the yield by biopsy type in tumour samples? 
## # A tibble: 2 × 6 
##    biopsy.type   min_   Q1_ median_    Q3_  max_ 
##          <chr>  <dbl> <dbl>   <dbl>  <dbl> <dbl> 
## 1 image-guided 0.0000 0.621   1.955  3.385 18.72 
## 2     surgical 0.0556 1.956   4.640 10.140 35.20 
Plot DNA yield by biopsy type 
## Warning: Removed 21 rows containing non-finite values (stat_boxplot). 
## Warning: Removed 21 rows containing non-finite values (stat_summary). 
 
Does the DNA yield differ by the type of biopsy? 
##   statistic     p.value                                            method 
## 1    1919.5 4.32916e-06 Wilcoxon rank sum test with continuity correction 
Goranova et al – Supplementary material 
 23 
##   alternative 
## 1   two.sided 
How many samples with > 200ng DNA? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   158 
How many patients with a sample > 200ng? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   124 
What was dissection method for samples with > 200ng of DNA? 
## # A tibble: 2 × 2 
##   dissection.method     n 
##               <chr> <int> 
## 1             Macro    40 
## 2             Micro   118 
What is the yield by needle size? 
## Warning: Removed 14 rows containing non-finite values (stat_boxplot). 
## Warning: Removed 14 rows containing non-finite values (stat_summary). 
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We summarize yield using the derived column "needle.size.bin" 
## # A tibble: 2 × 6 
##   needle.size.bin  min_   Q1_ median_   Q3_  max_ 
##             <chr> <dbl> <dbl>   <dbl> <dbl> <dbl> 
## 1         14G+16G 0.222 0.848   2.860  5.54 18.72 
## 2             18G 0.000 0.472   0.888  2.92 10.96 
Are differences in yield from needle size significant? Test hypothesis with non-parametric test. 
##   statistic    p.value                                            method 
## 1    1167.5 0.01062334 Wilcoxon rank sum test with continuity correction 
##   alternative 
## 1   two.sided 
What was the yield by biopsy location using recoded sites (both surgical and image guided)? 
## Source: local data frame [16 x 7] 
## Groups: biopsy.type [?] 
##  
##     biopsy.type    biopsy.site.recode   min_    Q1_ median_     Q3_  max_ 
##           <chr>                 <chr>  <dbl>  <dbl>   <dbl>   <dbl> <dbl> 
## 1  image-guided           gynae.organ 0.3800 3.1580  8.8200 13.3600 17.40 
## 2  image-guided                 liver 0.4720 0.6815  0.8000  1.6080  4.60 
## 3  image-guided            lymph.node 0.2220 0.6270  2.3200  3.1750 18.72 
## 4  image-guided               omentum 0.0520 0.7410  0.8700  2.9850  3.46 
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## 5  image-guided                 other 0.4040 0.4340  1.2000  3.4370  7.88 
## 6  image-guided            peritoneum 0.0000 0.6240  2.8600  4.5600 14.08 
## 7  image-guided subcut.abdochest.wall 0.3300 0.6200  0.7660  1.6590  3.36 
## 8      surgical   bowel.serosa.mesent 0.0800 1.8320  6.3200  7.8800 11.76 
## 9      surgical             diaphragm 0.0556 0.8117  1.5678  2.3239  3.08 
## 10     surgical           gynae.organ 0.4400 0.6480  2.1000 13.3200 19.44 
## 11     surgical            lymph.node 0.5160 1.6150  3.8700 15.0600 35.20 
## 12     surgical               omentum 0.9320 1.4650  4.5560  7.6800 14.64 
## 13     surgical                 other 1.0800 4.6400  6.2400  7.9900 18.16 
## 14     surgical          peri.splenic 2.6000 3.6800  5.2000  8.0900 13.28 
## 15     surgical            peritoneum 3.3000 5.7600 10.0600 11.9300 20.40 
## 16     surgical subcut.abdochest.wall 0.5120 3.9600  4.8000 12.2000 20.40 
Plot data for total DNA by tissue site. 
 
Are cellularity and total DNA yield correlated? 
## Warning: Removed 21 rows containing non-finite values (stat_smooth). 
## Warning: Removed 21 rows containing missing values (geom_point). 
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##    estimate statistic      p.value                          method 
## 1 0.3044246  502041.3 7.785379e-05 Spearman's rank correlation rho 
##   alternative 
## 1   two.sided 
TAm-seq 
Are the technical replicates consistent? For sequencing depth? 
## Warning: Removed 7 rows containing non-finite values (stat_smooth). 
## Warning: Removed 7 rows containing missing values (geom_point). 
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For allele fraction? 
## Warning: Removed 7 rows containing non-finite values (stat_smooth). 
## Warning: Removed 7 rows containing missing values (geom_point). 
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What was the sequencing depth and allele fraction (using mean of technical replicates)? 
## # A tibble: 1 × 6 
##   mean.depth_median_ mean.af_median_ mean.depth_min_ mean.af_min_ 
##                <dbl>           <dbl>           <dbl>        <dbl> 
## 1            1086.25         0.55375             154   0.01666992 
## # ... with 2 more variables: mean.depth_max_ <dbl>, mean.af_max_ <dbl> 
We join tam.seq data to the dna and biopsy data. 
## Joining, by = c("jblab.id", "trialno") 
Are cellularity and mean allele fraction related? 
## Warning: Removed 8 rows containing non-finite values (stat_smooth). 
## Warning: Removed 8 rows containing missing values (geom_point). 
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##    estimate statistic      p.value                          method 
## 1 0.3142648    623059 2.160671e-05 Spearman's rank correlation rho 
##   alternative 
## 1   two.sided 
Are DNA yield and mean allele fraction related? 
## Warning: Removed 8 rows containing non-finite values (stat_smooth). 
## Warning: Removed 8 rows containing missing values (geom_point). 
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##    estimate statistic     p.value                          method 
## 1 0.2199494    708754 0.003355179 Spearman's rank correlation rho 
##   alternative 
## 1   two.sided 
How many unique patients had tagged amplicon sequencing? 
## # A tibble: 1 × 1 
##       n 
##   <int> 
## 1   125 
How many patients had a mutation? 
## # A tibble: 5 × 2 
##     gene     n 
##    <chr> <int> 
## 1   KRAS     6 
## 2 PIK3CA     3 
## 3   PTEN     2 
## 4   TP53   118 
## 5   <NA>     4 
How many unique samples had tagged amplicon sequencing? 
## # A tibble: 1 × 1 
##       n 
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##   <int> 
## 1   160 
Which cases had multiple samples with TP53 mutations? 
## # A tibble: 118 × 2 
##    trialno     n 
##      <int> <int> 
## 1       32     7 
## 2       27     4 
## 3       45     4 
## 4       74     4 
## 5       88     4 
## 6       94     4 
## 7      103     4 
## 8        1     3 
## 9        2     2 
## 10       5     2 
## # ... with 108 more rows 
What is proportion of binned TP53 mutations? 
## # A tibble: 3 × 3 
##   tp53.type.recode     n      freq 
##              <chr> <int>     <dbl> 
## 1    nonsynonymous    71 60.169492 
## 2       truncating    41 34.745763 
## 3          inframe     6  5.084746 
What is proportion of all TP53 mutation types? 
## # A tibble: 9 × 3 
##                   type     n       freq 
##                  <chr> <int>      <dbl> 
## 1        nonsynonymous    71 60.1694915 
## 2       frameshift_del    14 11.8644068 
## 3      splice_acceptor     8  6.7796610 
## 4       frameshift_ins     7  5.9322034 
## 5          stop_gained     7  5.9322034 
## 6     inframe_deletion     5  4.2372881 
## 7         splice_donor     4  3.3898305 
## 8    inframe_insertion     1  0.8474576 
## 9 splice_region,intron     1  0.8474576 
 
 
